Enhancing Prediction Performance by Add-On Combining Circulating Tumor Cell Count, CD45neg EpCAMneg Cell Count on Colorectal Cancer, Advance, and Metastasis
Open Access
Abstract
Conventional circulating tumor cell (CTC) enumeration could ignore the CTCs more relevant to cancer metastasis. Thus, negative selection CTC enumeration was proposed, by which information on two cellular biomarkers (numbers of CTCs and CD45neg EpCAMneg cells) can be obtained. By combining this approach with the conventional biomarker carcinoembryonic antigen (CEA), this study aimed to explore whether any combination of these biomarkers could improve the predictive performance for colorectal cancer (CRC) or its status. In this work, these two cell populations in healthy donors and CRC patients were quantified. Results revealed that enumeration of these two cell populations was able to discriminate healthy donors from CRC patients, even patients with non-advanced CRC. Moreover, the combination of the two cell populations showed improved performance (AUROC: 0.893) for CRC prediction over the use of only one population. Compared with CEA alone, the combination of the three biomarkers increased the performance (AUROC) for advanced CRC prediction from 0.643 to 0.727. Compared with that of CEA alone for metastatic CRC prediction, the AUROC was increased from 0.780 to 0.837 when the CTC count was included. Overall, this study demonstrated that the combination of these two cellular biomarkers with CEA improved the predictive performance for CRC and its status.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 107-2221-E-182-033-MY3; MOST 109-2314-B-182-038-MY3)
- Chang Gung Memorial Hospital (CMRPD2H0121-23 and CMRPD2J0031-33)
- Chang Gung University (BMRP-B81)
This publication has 43 references indexed in Scilit:
- Clinical utility of circulating tumor cell counting through CellSearch®: the dilemma of a concept suspended in LimboOncoTargets and Therapy, 2014
- The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysisActa Oncologica, 2014
- Elevation of Preoperative s-CEA Concentration in Stage IIA Colorectal Cancer Can Also Be a High Risk Factor for Stage II PatientsAnnals of Surgical Oncology, 2013
- Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancerAnnals of Oncology, 2012
- Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resectionWorld Journal of Gastroenterology, 2012
- C-stage in Colon Cancer: Implications of Carcinoembryonic Antigen Biomarker in Staging, Prognosis, and ManagementJNCI: Journal of the National Cancer Institute, 2011
- Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the ClinicJournal of Oncology, 2009
- Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancerAnnals of Oncology, 2009
- Free DNA and Carcinoembryonic Antigen Serum Levels: An Important Combination for Diagnosis of Colorectal CancerClinical Cancer Research, 2006
- Metastasis: a question of life or deathNature Reviews Cancer, 2006